Latest
By Philip Joens / Friday, December 4th, 2015 / Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies / Comments Off on Amgen seeks European OK of biosimilar drug, partners with Merck on studies
Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →
Read More →
Latest
By Staff Report / Wednesday, November 25th, 2015 / Central Coast Health Watch, Latest news, Top Stories / Comments Off on Amgen asks FDA to approve biosimilar drug
Amgen submitted an application to the Food and Drug Administration for approval of its biosimilar drug ABP 501 on Nov. 25. ABP 501 is designed as a lower-cost version of Humira, which is approved to treat nine conditions including arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based AbbVie, typically costs $20,000 per year Read More →
Read More →
